Carl Zeiss Meditec (OTCMKTS:CZMWY) Rating Lowered to Strong Sell at Zacks Research

Carl Zeiss Meditec (OTCMKTS:CZMWY) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

Separately, UBS Group downgraded Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Carl Zeiss Meditec currently has a consensus rating of “Reduce”.

Carl Zeiss Meditec Trading Down 3.9%

Shares of OTCMKTS:CZMWY opened at $34.41 on Tuesday. Carl Zeiss Meditec has a 12-month low of $26.65 and a 12-month high of $55.94. The business’s fifty day simple moving average is $32.16 and its 200-day simple moving average is $31.08.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.